Primary Care Providers' Perspectives on Using Automated HIV Risk Prediction Models to Identify Potential Candidates for Pre-exposure Prophylaxis.


Journal

AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133

Informations de publication

Date de publication:
Nov 2021
Historique:
accepted: 25 03 2021
pubmed: 3 4 2021
medline: 4 11 2021
entrez: 2 4 2021
Statut: ppublish

Résumé

Identifying patients at increased risk for HIV acquisition can be challenging. Primary care providers (PCPs) may benefit from tools that help them identify appropriate candidates for HIV pre-exposure prophylaxis (PrEP). We and others have previously developed and validated HIV risk prediction models to identify PrEP candidates using electronic health records data. In the current study, we convened focus groups with PCPs to elicit their perspectives on using prediction models to identify PrEP candidates in clinical practice. PCPs were receptive to using prediction models to identify PrEP candidates. PCPs believed that models could facilitate patient-provider communication about HIV risk, destigmatize and standardize HIV risk assessments, help patients accurately perceive their risk, and identify PrEP candidates who might otherwise be missed. However, PCPs had concerns about patients' reactions to having their medical records searched, harms from potential breaches in confidentiality, and the accuracy of model predictions. Interest in clinical decision-support for PrEP was greatest among PrEP-inexperienced providers. Successful implementation of prediction models will require tailoring them to providers' preferences and addressing concerns about their use.

Identifiants

pubmed: 33797668
doi: 10.1007/s10461-021-03252-6
pii: 10.1007/s10461-021-03252-6
pmc: PMC8631042
mid: NIHMS1757729
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3651-3657

Subventions

Organisme : Rhode Island IDeA-CTR
ID : U54GM11567
Organisme : US Centers for Disease Control and Prevention through the STD Surveillance Network
ID : SSuN, CDC-RFA-PS13-1306
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM115677
Pays : United States
Organisme : NCHHSTP CDC HHS
ID : H25 PS004253
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH098795
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Lancet. 2014 Feb 1;383(9915):399-400
pubmed: 24494225
Med J Aust. 2013 Oct 7;199(7):485-9
pubmed: 24099210
AIDS Behav. 2017 May;21(5):1256-1267
pubmed: 27885552
AIDS Behav. 2014 Sep;18(9):1712-21
pubmed: 24965676
PLoS One. 2012;7(7):e40603
pubmed: 22792384
J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):285-292
pubmed: 28187084
Clin Infect Dis. 2017 Oct 30;65(10):1768-1769
pubmed: 29020235
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
BMJ Open. 2016 May 17;6(5):e011654
pubmed: 27188815
JAMA. 2019 Jun 11;321(22):2203-2213
pubmed: 31184747
Lancet HIV. 2019 Oct;6(10):e688-e695
pubmed: 31285183
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
PLoS One. 2016 Jun 03;11(6):e0156592
pubmed: 27258374
AIDS Patient Care STDS. 2019 Aug;33(8):372-378
pubmed: 31210551
Ann Epidemiol. 2020 May;45:24-31.e3
pubmed: 32336655
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
J Int Assoc Provid AIDS Care. 2016 Jan-Feb;15(1):59-65
pubmed: 26293904
J Gen Intern Med. 2017 Feb;32(2):192-198
pubmed: 27761767
Lancet HIV. 2019 Oct;6(10):e696-e704
pubmed: 31285182
Clin Infect Dis. 2015 Nov 15;61(10):1601-3
pubmed: 26334052
J Am Coll Cardiol. 2015 Apr 7;65(13):1361-1368
pubmed: 25835448
MMWR Morb Mortal Wkly Rep. 2019 Dec 06;68(48):1117-1123
pubmed: 31805031
JAMA. 2018 Apr 3;319(13):1317-1318
pubmed: 29532063
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279

Auteurs

Polly van den Berg (P)

Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Lowry Medical Office Building Suite GB, 110 Francis Street, Boston, MA, 02215, USA. pvan@bidmc.harvard.edu.

Victoria E Powell (VE)

University of Massachusetts Medical School, Worcester, MA, USA.

Ira B Wilson (IB)

Division of Health Services, Policy and Practice, Brown University, Providence, RI, USA.

Michael Klompas (M)

Department of Population Medicine, Harvard Medical School, Boston, MA, USA.
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.

Kenneth Mayer (K)

Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Lowry Medical Office Building Suite GB, 110 Francis Street, Boston, MA, 02215, USA.
The Fenway Institute, Fenway Health, Boston, MA, USA.

Douglas S Krakower (DS)

Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Lowry Medical Office Building Suite GB, 110 Francis Street, Boston, MA, 02215, USA.
Department of Population Medicine, Harvard Medical School, Boston, MA, USA.
The Fenway Institute, Fenway Health, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH